ArticleJournal of clinical microbiology2019
The New, New Daptomycin Breakpoint for
Article in Journal of clinical microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Understanding Daptomycin Resistance Mechanisms and Treatment Challenges inAntibiotics (Basel, Switzerland) · 2026Article
- Therapeutic approach to difficult-to-treat multidrug-resistant enterococcal infections.Antimicrobial agents and chemotherapy · 2025Review
- LiaX is a surrogate marker for cell envelope stress and daptomycin non-susceptibility inAntimicrobial agents and chemotherapy · 2024Article
- Antimicrobial resistance in Enterococcus isolated from western Canadian cow-calf herds.BMC veterinary research · 2024Article
- Phage-Antibiotic Cocktail Rescues Daptomycin and Phage Susceptibility against Daptomycin-Nonsusceptible Enterococcus faecium in a Simulated Endocardial VegetationMicrobiology spectrum · 2023Article
- Treatment decisions in VRE bacteraemia: a survey of infectious diseases pharmacists.JAC-antimicrobial resistance · 2023Article
- Article
- Daptomycin-ResistantOpen forum infectious diseases · 2022Article
- Polymyxin and lipopeptide antibiotics: membrane-targeting drugs of last resort.Microbiology (Reading, England) · 2022Review
- Daptomycin versus Glycopeptides for the Treatment ofAntibiotics (Basel, Switzerland) · 2021Article
- Daptomycin Resistance Occurs Predominantly inFrontiers in microbiology · 2021Article
- Mechanistic Insights Into the Differential Efficacy of Daptomycin Plus β-Lactam Combinations Against Daptomycin-Resistant Enterococcus faecium.The Journal of infectious diseases · 2020Article
- One Size Fits All? Application of Susceptible-Dose-Dependent Breakpoints to Pediatric Patients and Laboratory Reporting.Journal of clinical microbiology · 2019Review
- Optimizing the Dosing Regimens of Daptomycin Based on the Susceptible Dose-Dependent Breakpoint against Vancomycin-Resistant Enterococci Infection.Antibiotics (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2019, the Clinical and Laboratory Standards Institute revised the daptomycin breakpoints for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.